Article
Pyoderma gangrenosum (PG) is rare, but often associated with different forms of arthritis, in particular rheumatoid arthritis and inflammatory bowel diseases.
All News
Article
Dr. Jack Cush reviews the top abstracts from EULAR 2022 As chosen by me with the aid of the RheumNow EULAR faculty.
Article
What can we learn from Oral Surveillance?
The Oral Surveillance trial has almost become a household word for rheumatologists.
Article
Rheumatologists have long hoped and wondered whether the right type of early intervention could prevent rheumatoid arthritis occurring in at-risk individuals.
Article
An Annals of Internal Medicine review has shown that clinical trials and cohort studies of cannabinoids use for chronic pain may be associated with short-term improvements in chronic pain but come with an increased risk for dizziness and sedation.
Dr. John Cush
Tweet
Balance and falls studied in 228 #RA pts (24-85 yrs) followed x 1yr; 20% had at least one fall; risks included Age (OR 1.04), HAQ (OR 1.62), low FICSIT-4 score (OR 2.38) & 1-leg standing (OR 2.14). 1-leg stand is a good screening tool https://t.co/u9v8unC0gA https://t.co/oD0sgFxiQm
Dr. John Cush
Tweet
Small study 34 biologic-naive RA pts starting abatacept. Remission achieved 47.1% of early and 23.5% established RA. Remission @ 6 mos predicted by Baseline LOWER IL-6 levels ≤ 8.4 pg/ml, (66.7%) and CD4+CD25+FoxP3+ cells ≥ 6% (83.3%) https://t.co/N93E9M4M15
Dr. John Cush
Tweet
There are 494K PCPs in the USA, While up to 1/3 will "refill" DMARDs, only 6-9% are confident or knowledgeable in "initiating" DMARD therapy in #RA. GIGANTIC NEED FOR PCP education in MSK & Rheum Dz https://t.co/VjgWWDt3nX https://t.co/dTRXxsrzG5
Dr. John Cush
Tweet
Study of interferon (IFN) gene signature (IGS) finds IGS elevated in half of early RA pts; high IGS portends higher DAS28, fewer EULAR good resp & higher IFN-α; the latter assoc w/ epigentic changes, more lymphoctye activation. IFN-α as a biomarker? https://t.co/BHC98OR30A https://t.co/SRE7KVaoha
Dr. John Cush
Tweet
GLORIA Study Pred vs PBO in >65yrs RA x 2 years. 451 Pts & DAS28 4.5. 79% on DMARDs (14% biologics)
Upside: Lower DAS28 -0.37 & less Xray progression -1.7 Sharp units
Downside: 24% more AE (mild infxns), signif.small lowering of lumbar BMD -1%
You Decide
https://t.co/RRq0WcFsXz https://t.co/xLxjPPSMhh
Dr. John Cush
Tweet
CV risk factors not equal when considering magnitude of risk
What can we learn from Oral Surveillance?
The Oral Surveillance trial has almost become a household word for rheumatologists.
https://t.co/LHZTVZh4AK https://t.co/2SlxrG7UpQ
Dr. John Cush
Tweet
Can we stop RA before it happens?
Rheumatologists have long hoped and wondered whether the right type of early intervention could prevent RA occurring in at-risk individuals.
https://t.co/vU4tRr7UJh https://t.co/cikU9pwaiT
Dr. John Cush
Tweet
Watch: RA Potpourri on Day One EULAR 2022: Not An Ugly Duckling
https://t.co/Lp25lP6ZZY https://t.co/wd5GCbaCLR
Dr. John Cush
Tweet
Video: Residual Pain in RA
Dr. Maxime Dougados discusses OP0052 at #EULAR2022.
https://t.co/gu1Svegss8 https://t.co/G1rRizG9gW
Dr. John Cush
Tweet
Canadian study of 50,883 RA pts shows only 58% saw a rheumatologist yearly for 5 yrs. If >65 yrs, Rheum care assoc w/ DMARD use in 82%; but was only 31% if not under Rheum care. Worse rheum retention with age >81, male, lower SES, older Rheums https://t.co/xUxWaksgsE
Dr. John Cush
Tweet
FDA approved another rituximab biosimilar, rituximab-arrx (Riabni) (from Amgen), for use w/ MTX in active RA. Riabni is not currently approved for B-cell NHL, B-cell leukemia, MPA, or GPA. or pemphigus vulgaris (RTX is an orphan drug) https://t.co/Htk0xBx63X https://t.co/ep1L3YO9hl
Dr. John Cush
Tweet
Watch: Major Consequences of Depression In RA
https://t.co/aVzIHDiRZ4 https://t.co/86RLXJKb64
Dr. John Cush
Tweet
VIDEO: No Glory in GLORIA
Dr. Richard Conway discusses abstract OP0263 presented at #EULAR2022.
https://t.co/tlsTPztYqY https://t.co/5dOma69vLZ
Dr. John Cush
Tweet
Watch: Let’s Talk about Sex and Autoimmune Disease
Dr. Eric Dein discusses abstract OP0139 presented at #EULAR2022.
https://t.co/fNcIbykFqL https://t.co/6UaH5DIc51
Dr. John Cush
Tweet
Watch: Demystifying Synovial Tissue Biology
Dr. Aurelie Najm ( @AurelieRheumo) discusses abstracts OP0084 and OP0085 presented at #EULAR2022.
https://t.co/LNfFmxiE8O https://t.co/aiLvdtxYRB
